Skip to main content

Table 2 Whole genome sequencing

From: Whole genome sequencing reveals potential targets for therapy in patients with refractory KRASmutated metastatic colorectal cancer

Participant code

Total reads sequenced

Total bases sequenced

Coverage

Number of germline variants

Percent dbSNP

Transition/transversion ratio

CLN2 Normal

1.9 billion

200 Gb

50X

2.3 million

88%

2.05

CLN2 Tumor

1.4 billion

146 Gb

42X

—

  

CLN3 Normal

2.0 billion

210 Gb

62X

3.4 million

88%

2.06

CLN3 Tumor

1.96 billion

204 Gb

40X

—

  

CLN4 Normal

0.97 billion

100 Gb

28X

3.3 million

88%

2.06

CLN4 Tumor

1.03 billion

107 Gb

31X

—

 Â